InChI=1S/C19H21NO4.ClH/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11;/h2-4,14,17,21,23H,1,5-10H2;1H/t14-,17+,18+,19-;/m1./s1 |
RGPDIGOSVORSAK-STHHAXOLSA-N |
C1=2C[C@@H]3[C@@]4(CCC([C@H]5[C@@]4(C1=C(C(=CC2)O)O5)CCN3CC=C)=O)O.Cl |
|
mu-opioid receptor antagonist
Any compound that exhibits antagonist activity at the mu-opioid receptor
|
|
central nervous system depressant
A loosely defined group of drugs that tend to reduce the activity of the central nervous system.
antidote to opioid poisoning
A role borne by a molecule that acts to counteract or neutralise the deleterious effects of opioids.
mu-opioid receptor antagonist
Any compound that exhibits antagonist activity at the mu-opioid receptor
|
|
View more via ChEBI Ontology
17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one hydrochloride
|
(17R)-17-allyl-3,14-dihydroxy-6-oxo-4,5α-epoxymorphinan-17-ium chloride
|
IUPAC
|
(5α)-17-allyl-3,14-dihydroxy-4,5-epoxymorphinan-6-one hydrochloride
|
IUPAC
|
(5α,17R)-17-allyl-3,14-dihydroxy-6-oxo-4,5-epoxymorphinan-17-ium chloride
|
IUPAC
|
357-08-4
|
CAS Registry Number
|
KEGG DRUG
|
357-08-4
|
CAS Registry Number
|
ChemIDplus
|
3641068
|
Reaxys Registry Number
|
Reaxys
|
2180244
|
PubMed citation
|
Europe PMC
|
25705253
|
PubMed citation
|
Europe PMC
|
25738001
|
PubMed citation
|
Europe PMC
|
2986307
|
PubMed citation
|
Europe PMC
|
4648550
|
PubMed citation
|
Europe PMC
|
|